Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 18 | 2023 | 66 | 6.050 |
Why?
|
| Rhinitis | 17 | 2023 | 59 | 5.980 |
Why?
|
| Endoscopy | 14 | 2023 | 83 | 1.870 |
Why?
|
| Paranasal Sinuses | 7 | 2022 | 30 | 1.860 |
Why?
|
| Chronic Disease | 17 | 2023 | 186 | 1.600 |
Why?
|
| Retrospective Studies | 28 | 2023 | 1467 | 1.470 |
Why?
|
| Humans | 61 | 2023 | 12240 | 1.390 |
Why?
|
| Nose Neoplasms | 5 | 2020 | 12 | 1.350 |
Why?
|
| Paranasal Sinus Neoplasms | 4 | 2021 | 20 | 1.310 |
Why?
|
| Head and Neck Neoplasms | 4 | 2021 | 57 | 1.150 |
Why?
|
| Melanoma | 3 | 2021 | 34 | 1.140 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 3 | 2019 | 4 | 1.070 |
Why?
|
| Nasal Cavity | 3 | 2019 | 12 | 1.060 |
Why?
|
| Nasal Polyps | 3 | 2023 | 14 | 1.050 |
Why?
|
| Female | 34 | 2021 | 6974 | 0.940 |
Why?
|
| Middle Aged | 27 | 2021 | 4043 | 0.910 |
Why?
|
| Male | 30 | 2021 | 6815 | 0.870 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 24 | 0.850 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 40 | 0.740 |
Why?
|
| Ethmoid Sinus | 2 | 2017 | 6 | 0.640 |
Why?
|
| Nasal Surgical Procedures | 2 | 2019 | 2 | 0.640 |
Why?
|
| Laryngopharyngeal Reflux | 1 | 2020 | 2 | 0.630 |
Why?
|
| Optical Imaging | 2 | 2017 | 2 | 0.620 |
Why?
|
| Laryngeal Neoplasms | 4 | 2021 | 12 | 0.620 |
Why?
|
| Eosinophils | 1 | 2019 | 15 | 0.610 |
Why?
|
| Eosinophilia | 1 | 2019 | 13 | 0.610 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 45 | 0.590 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 48 | 0.590 |
Why?
|
| Insurance Coverage | 1 | 2019 | 7 | 0.580 |
Why?
|
| Maxillary Sinus Neoplasms | 2 | 2020 | 3 | 0.570 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 165 | 0.570 |
Why?
|
| Treatment Outcome | 11 | 2023 | 1478 | 0.560 |
Why?
|
| Prognosis | 8 | 2021 | 363 | 0.560 |
Why?
|
| Quality of Life | 2 | 2020 | 261 | 0.560 |
Why?
|
| Osteoblastoma | 1 | 2018 | 3 | 0.550 |
Why?
|
| Aged | 17 | 2021 | 4000 | 0.530 |
Why?
|
| Survival Rate | 8 | 2021 | 152 | 0.520 |
Why?
|
| Lacrimal Apparatus | 1 | 2017 | 1 | 0.520 |
Why?
|
| Adult | 16 | 2023 | 3557 | 0.520 |
Why?
|
| Therapeutic Irrigation | 1 | 2017 | 27 | 0.510 |
Why?
|
| Stents | 1 | 2017 | 28 | 0.510 |
Why?
|
| Betacoronavirus | 4 | 2020 | 38 | 0.500 |
Why?
|
| Smell | 1 | 2016 | 9 | 0.490 |
Why?
|
| Frontal Sinusitis | 1 | 2016 | 1 | 0.480 |
Why?
|
| Frontal Sinus | 1 | 2016 | 3 | 0.480 |
Why?
|
| Otolaryngology | 3 | 2021 | 14 | 0.480 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 43 | 0.480 |
Why?
|
| Dissection | 1 | 2016 | 16 | 0.480 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 70 | 0.470 |
Why?
|
| Biofilms | 1 | 2016 | 2 | 0.470 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 168 | 0.460 |
Why?
|
| Databases, Factual | 5 | 2021 | 156 | 0.420 |
Why?
|
| Child | 10 | 2021 | 614 | 0.420 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 281 | 0.410 |
Why?
|
| Temporal Bone | 2 | 2010 | 5 | 0.390 |
Why?
|
| Sarcoma | 1 | 2014 | 59 | 0.380 |
Why?
|
| Adolescent | 9 | 2019 | 989 | 0.370 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 423 | 0.360 |
Why?
|
| Young Adult | 8 | 2019 | 863 | 0.360 |
Why?
|
| Skull Base | 3 | 2021 | 13 | 0.350 |
Why?
|
| Tongue Neoplasms | 2 | 2021 | 10 | 0.310 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2010 | 2 | 0.310 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2010 | 16 | 0.310 |
Why?
|
| Pituitary Neoplasms | 2 | 2020 | 5 | 0.310 |
Why?
|
| Rhinitis, Allergic | 2 | 2020 | 11 | 0.290 |
Why?
|
| Preoperative Period | 2 | 2019 | 34 | 0.290 |
Why?
|
| United States | 5 | 2021 | 989 | 0.280 |
Why?
|
| Survival Analysis | 5 | 2021 | 99 | 0.270 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 151 | 0.260 |
Why?
|
| Pandemics | 4 | 2020 | 126 | 0.260 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 324 | 0.220 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 2152 | 0.210 |
Why?
|
| Nose | 3 | 2021 | 13 | 0.210 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 143 | 0.210 |
Why?
|
| Laryngectomy | 2 | 2021 | 7 | 0.200 |
Why?
|
| Nasal Obstruction | 1 | 2023 | 1 | 0.190 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 726 | 0.190 |
Why?
|
| Rhinoplasty | 1 | 2023 | 9 | 0.190 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 20 | 0.180 |
Why?
|
| Mometasone Furoate | 1 | 2022 | 4 | 0.180 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 5 | 0.180 |
Why?
|
| SEER Program | 3 | 2018 | 8 | 0.170 |
Why?
|
| Social Media | 1 | 2022 | 32 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 22 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 40 | 0.170 |
Why?
|
| Radiology | 1 | 2021 | 8 | 0.170 |
Why?
|
| Encephalocele | 1 | 2021 | 6 | 0.170 |
Why?
|
| Microbiota | 2 | 2018 | 35 | 0.170 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 17 | 0.170 |
Why?
|
| Chondrosarcoma | 1 | 2021 | 17 | 0.170 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 61 | 0.170 |
Why?
|
| Air Pollutants | 1 | 2021 | 10 | 0.170 |
Why?
|
| Air Pollution | 1 | 2021 | 13 | 0.170 |
Why?
|
| Observer Variation | 1 | 2021 | 47 | 0.160 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2020 | 2 | 0.160 |
Why?
|
| Natural Killer T-Cells | 1 | 2020 | 3 | 0.160 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2018 | 17 | 0.160 |
Why?
|
| Empty Sella Syndrome | 1 | 2020 | 3 | 0.160 |
Why?
|
| Glottis | 1 | 2020 | 3 | 0.160 |
Why?
|
| Eczema | 1 | 2020 | 2 | 0.160 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 78 | 0.160 |
Why?
|
| Hemostatic Techniques | 1 | 2020 | 6 | 0.160 |
Why?
|
| Epistaxis | 1 | 2020 | 9 | 0.160 |
Why?
|
| Food Hypersensitivity | 1 | 2020 | 17 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 8 | 0.160 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 51 | 0.160 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 6 | 0.160 |
Why?
|
| Cryosurgery | 1 | 2020 | 12 | 0.160 |
Why?
|
| Airway Management | 1 | 2020 | 12 | 0.160 |
Why?
|
| Urban Health Services | 1 | 2020 | 7 | 0.160 |
Why?
|
| Pharynx | 1 | 2020 | 8 | 0.160 |
Why?
|
| Tracheostomy | 1 | 2020 | 9 | 0.160 |
Why?
|
| Neurosurgical Procedures | 1 | 2021 | 57 | 0.160 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 15 | 0.160 |
Why?
|
| Simulation Training | 1 | 2020 | 15 | 0.160 |
Why?
|
| Incidence | 3 | 2019 | 338 | 0.160 |
Why?
|
| Olfaction Disorders | 1 | 2020 | 24 | 0.160 |
Why?
|
| Risk Factors | 4 | 2020 | 1049 | 0.160 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 12 | 0.150 |
Why?
|
| Leukocyte Count | 1 | 2019 | 35 | 0.150 |
Why?
|
| Carcinoma | 1 | 2020 | 34 | 0.150 |
Why?
|
| Disease Management | 1 | 2020 | 59 | 0.150 |
Why?
|
| Drug-Eluting Stents | 1 | 2019 | 5 | 0.150 |
Why?
|
| Steroids | 1 | 2019 | 12 | 0.150 |
Why?
|
| Smoking | 1 | 2020 | 84 | 0.150 |
Why?
|
| Trachea | 1 | 2020 | 33 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 45 | 0.150 |
Why?
|
| Asthma | 1 | 2020 | 76 | 0.150 |
Why?
|
| Nasal Mucosa | 1 | 2019 | 5 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2020 | 96 | 0.150 |
Why?
|
| Child, Preschool | 3 | 2016 | 320 | 0.150 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 23 | 0.150 |
Why?
|
| Craniopharyngioma | 1 | 2018 | 1 | 0.140 |
Why?
|
| Sphenoid Bone | 1 | 2018 | 1 | 0.140 |
Why?
|
| Bacteroidetes | 1 | 2018 | 3 | 0.140 |
Why?
|
| Firmicutes | 1 | 2018 | 5 | 0.140 |
Why?
|
| Illinois | 1 | 2019 | 110 | 0.140 |
Why?
|
| Internship and Residency | 1 | 2020 | 103 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 34 | 0.140 |
Why?
|
| Neutrophils | 1 | 2018 | 58 | 0.140 |
Why?
|
| Osteoma | 1 | 2018 | 3 | 0.140 |
Why?
|
| Fibroma, Ossifying | 1 | 2018 | 3 | 0.140 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 66 | 0.140 |
Why?
|
| Lymphoma | 1 | 2018 | 16 | 0.130 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 3 | 0.130 |
Why?
|
| Pseudomonas Infections | 1 | 2017 | 17 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 69 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 59 | 0.130 |
Why?
|
| Parathyroid Glands | 1 | 2017 | 3 | 0.130 |
Why?
|
| Carcinoma, Small Cell | 1 | 2016 | 24 | 0.120 |
Why?
|
| Cadaver | 1 | 2017 | 166 | 0.120 |
Why?
|
| Age Factors | 4 | 2020 | 350 | 0.120 |
Why?
|
| Mucous Membrane | 1 | 2016 | 10 | 0.120 |
Why?
|
| Inflammation | 1 | 2017 | 124 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 18 | 0.120 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 27 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2016 | 21 | 0.120 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 22 | 0.110 |
Why?
|
| Reoperation | 1 | 2016 | 366 | 0.100 |
Why?
|
| Sex Factors | 3 | 2020 | 229 | 0.100 |
Why?
|
| Tertiary Healthcare | 1 | 2014 | 1 | 0.100 |
Why?
|
| Lymphatic Vessels | 1 | 2014 | 5 | 0.100 |
Why?
|
| California | 1 | 2014 | 27 | 0.100 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2014 | 4 | 0.100 |
Why?
|
| Elastic Modulus | 1 | 2014 | 6 | 0.100 |
Why?
|
| Viscosity | 1 | 2014 | 6 | 0.100 |
Why?
|
| Lymphocytes | 1 | 2014 | 30 | 0.100 |
Why?
|
| Transducers | 1 | 2014 | 7 | 0.100 |
Why?
|
| Image Enhancement | 1 | 2014 | 25 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 126 | 0.100 |
Why?
|
| Immunotherapy | 2 | 2021 | 27 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 161 | 0.080 |
Why?
|
| Hair Cells, Auditory | 1 | 2010 | 1 | 0.080 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2010 | 1 | 0.080 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2010 | 2 | 0.080 |
Why?
|
| Cochlear Implantation | 1 | 2010 | 5 | 0.080 |
Why?
|
| Actinomycosis | 1 | 2010 | 2 | 0.080 |
Why?
|
| Meningitis, Bacterial | 1 | 2010 | 2 | 0.080 |
Why?
|
| Speech Intelligibility | 1 | 2010 | 5 | 0.080 |
Why?
|
| Deafness | 1 | 2010 | 6 | 0.080 |
Why?
|
| Encephalitis | 1 | 2010 | 8 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 153 | 0.080 |
Why?
|
| Audiometry | 1 | 2010 | 2 | 0.080 |
Why?
|
| Comorbidity | 2 | 2020 | 209 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2023 | 817 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2021 | 385 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 141 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 827 | 0.050 |
Why?
|
| Nasal Septum | 1 | 2023 | 5 | 0.050 |
Why?
|
| Hypertrophy | 1 | 2023 | 10 | 0.050 |
Why?
|
| Temperature | 1 | 2023 | 33 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2022 | 8 | 0.040 |
Why?
|
| Video Recording | 1 | 2022 | 16 | 0.040 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2021 | 4 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 37 | 0.040 |
Why?
|
| Tongue | 1 | 2021 | 3 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2021 | 23 | 0.040 |
Why?
|
| Tourette Syndrome | 1 | 2021 | 8 | 0.040 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 2021 | 3 | 0.040 |
Why?
|
| Petrous Bone | 1 | 2021 | 3 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 85 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2021 | 16 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2021 | 14 | 0.040 |
Why?
|
| Particulate Matter | 1 | 2021 | 13 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 196 | 0.040 |
Why?
|
| Optic Chiasm | 1 | 2020 | 2 | 0.040 |
Why?
|
| Optic Nerve | 1 | 2020 | 2 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 21 | 0.040 |
Why?
|
| Neck Dissection | 1 | 2020 | 6 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 18 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 42 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 23 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 29 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 14 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 99 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 8 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 26 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 111 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 256 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 118 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 53 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 295 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2019 | 60 | 0.040 |
Why?
|
| Animals | 2 | 2017 | 2092 | 0.040 |
Why?
|
| Air | 1 | 2018 | 3 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 128 | 0.040 |
Why?
|
| Metaplasia | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 19 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 28 | 0.040 |
Why?
|
| Biodiversity | 1 | 2018 | 16 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 464 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 36 | 0.030 |
Why?
|
| Drug Design | 1 | 2017 | 9 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2017 | 6 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 290 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 118 | 0.030 |
Why?
|
| Necrosis | 1 | 2017 | 10 | 0.030 |
Why?
|
| Cranial Nerve Diseases | 1 | 2017 | 2 | 0.030 |
Why?
|
| Basement Membrane | 1 | 2017 | 5 | 0.030 |
Why?
|
| Fibrosis | 1 | 2017 | 15 | 0.030 |
Why?
|
| Edema | 1 | 2017 | 15 | 0.030 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2017 | 4 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 116 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 10 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 294 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 221 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2014 | 32 | 0.030 |
Why?
|
| Equipment Design | 1 | 2014 | 76 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 252 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 546 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hearing Tests | 1 | 2010 | 3 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 2010 | 5 | 0.020 |
Why?
|
| Speech Production Measurement | 1 | 2010 | 1 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2010 | 11 | 0.020 |
Why?
|
| Cochlear Implants | 1 | 2010 | 6 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 74 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 55 | 0.020 |
Why?
|
| Speech Perception | 1 | 2010 | 18 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 97 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 115 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 205 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2010 | 195 | 0.020 |
Why?
|
| Infant | 1 | 2010 | 277 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 695 | 0.020 |
Why?
|
| Mice | 1 | 2010 | 760 | 0.020 |
Why?
|